

Nico M Wulffraat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2178413/publications.pdf>

Version: 2024-02-01

240
papers

17,404
citations

11908

72
h-index

17891

125
g-index

242
all docs

242
docs citations

242
times ranked

13915
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. <i>Rheumatology</i> , 2023, 62, SI170-SI180.	0.9	4
2	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , 2022, 61, 2524-2534.	0.9	9
3	Costs of Hospital-Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. <i>Arthritis Care and Research</i> , 2022, 74, 1585-1592.	1.5	3
4	Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry. <i>Journal of Rheumatology</i> , 2022, 49, 398-407.	1.0	15
5	Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. <i>Patient</i> , 2022, 15, 599-609.	1.1	3
6	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 998-1005.	0.5	12
7	Challenging the silent temporomandibular joint paradigm in children with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2022, 20, 22.	0.9	1
8	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. <i>Pediatric Rheumatology</i> , 2022, 20, 25.	0.9	8
9	A Diagnostic Prediction Model for Separating Juvenile Idiopathic Arthritis and Chronic Musculoskeletal Pain Syndrome. <i>Journal of Pediatrics</i> , 2022, 251, 164-171.e6.	0.9	3
10	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	1.2	3
11	Growth curves for mandibular range of motion and maximum voluntary bite force in healthy children. <i>European Journal of Oral Sciences</i> , 2022, 130, e12869.	0.7	4
12	Preclinical Aortic Atherosclerosis in Adolescents With Chronic Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
13	A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 2896-2905.	0.9	14
14	Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 975-984.	0.7	8
15	Consensus-based recommendations for the management of juvenile systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 1651-1658.	0.9	20
16	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 336-346.	2.9	23
17	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. <i>RMD Open</i> , 2021, 7, e001594.	1.8	59
18	Monitoring patients with juvenile idiopathic arthritis using health-related quality of life. <i>Pediatric Rheumatology</i> , 2021, 19, 40.	0.9	6

#	ARTICLE	IF	CITATIONS
19	P055â€fWorry about COVID-19 amongst adult rheumatology patients in the UK is associated with the number of cases, and drives risk-reducing behaviours. <i>Rheumatology</i> , 2021, 60, .	0.9	0
20	Association of adalimumab trough concentrations and treatment response in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 61, 377-382.	0.9	2
21	O31â€fTrajectories of anxiety in children young people and adults with rheumatic diseases in the wake of COVID-19: results from the COVID-19 European patient registry. <i>Rheumatology</i> , 2021, 60, .	0.9	1
22	Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1303-1322.	1.1	6
23	Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. <i>Rheumatology</i> , 2021, , .	0.9	13
24	Genomic Health Literacy Interventions in Pediatrics: Scoping Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e26684.	2.1	4
25	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 39-52.	0.5	506
26	Whole Transcriptome Analysis Reveals Heterogeneity in B Cell Memory Populations in Patients With Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Frontiers in Immunology</i> , 2020, 11, 2170.	2.2	4
27	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Openâ€Label, Activeâ€Treatment Extension Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 2147-2158.	2.9	21
28	Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study. <i>Pediatric Rheumatology</i> , 2020, 18, 87.	0.9	4
29	Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study. <i>Lupus</i> , 2020, 29, 934-942.	0.8	18
30	Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance. <i>Pediatric Rheumatology</i> , 2020, 18, 12.	0.9	2
31	The Patient and Parent Perspective on Methotrexate in Recent Juvenile Idiopathic Arthritis Guidelines: Comment on the Article by Ringold et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1039-1040.	2.9	0
32	Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. <i>Vaccine</i> , 2020, 38, 2198-2201.	1.7	41
33	Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 33.	1.2	8
34	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. <i>Arthritis Research and Therapy</i> , 2020, 22, 71.	1.6	25
35	Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?. <i>Pediatric Rheumatology</i> , 2020, 18, 34.	0.9	15
36	The European network for care of children with paediatric rheumatic diseases: care across borders. <i>Rheumatology</i> , 2019, 58, 1188-1195.	0.9	15

#	ARTICLE	IF	CITATIONS
37	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2019, 54, 933-942.	1.3	25
38	Fatigue in childhood chronic disease. <i>Archives of Disease in Childhood</i> , 2019, 104, 1090-1095.	1.0	35
39	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 125.	1.6	31
40	Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. <i>Pediatric Rheumatology</i> , 2019, 17, 20.	0.9	10
41	Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients. <i>Rheumatology</i> , 2019, 58, 1812-1817.	0.9	11
42	Barbara Ansell: a person ahead of her time. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 725-728.	0.5	6
43	European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 1607-1616.	0.9	165
44	Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1163-1173.	2.9	129
45	Consensus-based recommendations for the management of juvenile localised scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1019-1024.	0.5	76
46	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	2.7	120
47	AB1072â€¦THE CONSEQUENCES OF THE PROVISIONAL PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION JUVENILE IDIOPATHIC ARTHRITIS CLASSIFICATION CRITERIA. , 2019, , .		0
48	THU0525â€¦DEVELOPMENT OF A PREDICTIVE TOOL FOR RESPONSE TO ANTI-TNF-ALPHA THERAPY IN JIA USING GENE EXPRESSION PROFILES IN PERIPHERAL DERIVED MONONUCLEAR CELLS. , 2019, , .		0
49	OP0055â€¦EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
50	OP0058â€¦DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE DURING TREATMENT WITH ETANERCEPT IN PATIENTSWITH JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
51	OP0205â€¦LIVE ATTENUATED VACCINES IN PEDIATRIC RHEUMATIC DISEASES ARE SAFE: MULTICENTER, RETROSPECTIVE DATA COLLECTION. , 2019, , .		2
52	SAT0494â€¦HOME MONITORING OF INACTIVE DISEASE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: PREDICTIVE VALUE OF EQ-5D-5L-Y. , 2019, , .		0
53	THU0666â€¦SERIOUS/AT LEAST MODERATE INFECTIONS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS ON SYNTHETIC AND BIOLOGIC DRUGS FROM THE PHARMACHILD REGISTRY. , 2019, , .		1
54	SAT0508â€¦AN INTERNATIONAL SURVEY ON APPROACHES TOWARDS IMMUNISATION IN CHILDREN WITH RHEUMATIC DISEASES: A REPORT OF THE PRES VACCINATIONS WORKING GROUP. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	SP0010â€¦INFECTIOUS RISK AND MANAGEMENT OF VACCINATION. , 2019, , .		0
56	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open, 2019, 5, e001041.	1.8	104
57	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open, 2019, 5, e001035.	1.8	113
58	Children and young people get rheumatic disease too. The Lancet Child and Adolescent Health, 2019, 3, 8-9.	2.7	9
59	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care and Research, 2019, 71, 1556-1565.	1.5	43
60	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides â€” the SHARE initiative. Rheumatology, 2019, 58, 656-671.	0.9	77
61	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease â€” the SHARE initiative. Rheumatology, 2019, 58, 672-682.	0.9	103
62	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	1.0	318
63	Identification of an Amino Acid Motif in <scp>HLA</scp> â€” <scp>DR</scp>Î²1 That Distinguishes Uveitis in Patients With Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1155-1165.	2.9	40
64	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrhumdis-2018-213030.	0.5	183
65	The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatric Rheumatology, 2018, 16, 19.	0.9	35
66	The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 139-146.	1.5	2
67	Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2018, 77, annrhumdis-2018-213131.	0.5	119
68	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.5	9
69	Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2018, 77, 336-342.	0.5	57
70	Educational initiatives and training for paediatric rheumatology in Europe. Pediatric Rheumatology, 2018, 16, 77.	0.9	10
71	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research and Therapy, 2018, 20, 285.	1.6	71
72	Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS ONE, 2018, 13, e0208534.	1.1	40

#	ARTICLE	IF	CITATIONS
73	The role of placebo effects in immune-related conditions: mechanisms and clinical considerations. Expert Review of Clinical Immunology, 2018, 14, 761-770.	1.3	8
74	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719.	0.5	79
75	Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol. Pediatric Rheumatology, 2018, 16, 57.	0.9	16
76	Patient's experiences with the care for juvenile idiopathic arthritis across Europe. Pediatric Rheumatology, 2018, 16, 10.	0.9	14
77	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clinical and Experimental Rheumatology, 2018, 36, 920-928.	0.4	8
78	The value of old drugs for juvenile idiopathic arthritis. Lancet, The, 2017, 389, 883-884.	6.3	4
79	Haematopoietic stem cell transplantation for autoimmune diseases. Nature Reviews Rheumatology, 2017, 13, 244-256.	3.5	108
80	Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. Vaccine, 2017, 35, 2818-2822.	1.7	26
81	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1637-1641.	0.5	75
82	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.5	139
83	Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. Blood, 2017, 129, 2928-2938.	0.6	31
84	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.5	105
85	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	0.9	50
86	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. Pediatric Rheumatology, 2017, 15, 31.	0.9	27
87	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy, 2017, 19, 13.	1.6	49
88	Internet Program for Physical Activity and Exercise Capacity in Children With Juvenile Idiopathic Arthritis: A Multicenter Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 1040-1049.	1.5	23
89	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	2.5	151
90	Fatigue in patients with Juvenile Idiopathic Arthritis: relationship to perceived health, physical health, self-efficacy, and participation. Pediatric Rheumatology, 2016, 14, 65.	0.9	38

#	ARTICLE	IF	CITATIONS
91	Pneumococcal Vaccination Strategies in the Real World of Chronically Ill Patients. <i>Journal of Rheumatology</i> , 2016, 43, 255-257.	1.0	1
92	Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. <i>Blood</i> , 2016, 127, 91-101.	0.6	87
93	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> . 2016. 68. 566-576.	2.9	427
94	Prevalence of Severe Fatigue Among Adolescents With Pediatric Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2016, 68, 108-114.	1.5	38
95	HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. <i>Pediatric Rheumatology</i> , 2016, 14, 12.	0.9	31
96	Immunodeficiencies and the Rheumatic Diseases. , 2016, , 597-608.e5.		1
97	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	1.8	57
98	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.5	338
99	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet, The</i> , 2016, 387, 671-678.	6.3	168
100	Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 148-54.	0.4	22
101	Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. <i>Blood</i> , 2015, 125, 2164-2172.	0.6	262
102	Design and acceptance of Rheumates@Work, a combined internet-based and in person instruction model, an interactive, educational, and cognitive behavioral program for children with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2015, 13, 31.	0.9	33
103	Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2015, 13, 55.	0.9	72
104	Temporomandibular joint involvement in Juvenile Idiopathic Arthritis: reliability and validity of a screening protocol for the rheumatologist. <i>Pediatric Rheumatology</i> , 2015, 13, 15.	0.9	12
105	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139
106	A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1961-1967.	1.0	13
107	Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment. <i>Journal of Rheumatology</i> , 2015, 42, 2211.2-2214.	1.0	24
108	Erythrocyte Sedimentation Rate as Baseline Predictor for the Development of Uveitis in Children With Juvenile Idiopathic Arthritis. <i>American Journal of Ophthalmology</i> , 2015, 159, 372-377.e1.	1.7	40

#	ARTICLE	IF	CITATIONS
109	Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1379-1386.	0.5	45
110	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 635-641.	0.5	145
111	Recommendations for the management of autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1636-1644.	0.5	239
112	Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study. <i>Pediatric Rheumatology</i> , 2015, 13, 5.	0.9	36
113	Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2015, 54, 1724-1734.	0.9	17
114	Vaccinations in Paediatric Rheumatology: an Update on Current Developments. <i>Current Rheumatology Reports</i> , 2015, 17, 46.	2.1	49
115	Use and perceived relevance of health-related Internet sites and online contact with peers among young people with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2015, 54, 1833-1841.	0.9	12
116	Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. <i>Rheumatology</i> , 2015, 54, 1008-1016.	0.9	141
117	Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 402-407.	0.5	46
118	Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 408-414.	0.5	66
119	Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1996-2005.	0.5	49
120	Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 843-854.	1.3	8
121	Evidence based recommendations for genetic diagnosis of Familial Mediterranean Fever. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	7
122	Use of internet in adolescents and young adults with JIA. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	0
123	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1114-1122.	0.5	106
124	Evaluation of anakinra for the treatment of systemic juvenile idiopathic arthritis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 181-188.	0.5	0
125	Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 949-955.	1.5	47
126	Mesenchymal stromal cells for treatment of arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 589-603.	1.4	16

#	ARTICLE	IF	CITATIONS
127	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. <i>Pediatric Rheumatology</i> , 2014, 12, 49.	0.9	6
128	Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. <i>Pediatric Rheumatology</i> , 2014, 12, 51.	0.9	26
129	Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	1
130	Brief Report: Autologous Stem Cell Transplantation Restores Immune Tolerance in Experimental Arthritis by Renewal and Modulation of the Teff Cell Compartment. <i>Arthritis and Rheumatology</i> , 2014, 66, 350-356.	2.9	12
131	Puberty and disease activity in JIA. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	0
132	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. <i>Arthritis and Rheumatology</i> , 2014, 66, S8-S9.	2.9	9
133	Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2014, 53, 307-312.	0.9	43
134	Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 1034-1043.	2.9	213
135	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1380-1383.	0.5	77
136	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	2.9	101
137	Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?. <i>Immunotherapy</i> , 2014, 6, 1-3.	1.0	3
138	Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis). <i>Pediatric Rheumatology</i> , 2014, 12, 18.	0.9	85
139	Periodic Fever in MVK Deficiency: A Patient Initially Diagnosed With Incomplete Kawasaki Disease. <i>Pediatrics</i> , 2014, 133, e461-e465.	1.0	12
140	Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 728-734.	0.5	32
141	Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown. <i>Survey of Ophthalmology</i> , 2014, 59, 517-531.	1.7	65
142	Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1500-1507.	0.5	56
143	Time to share. <i>Pediatric Rheumatology</i> , 2013, 11, 5.	0.9	61
144	Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1367-1375.e9.	1.5	107

#	ARTICLE	IF	CITATIONS
145	Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 721-727.	0.5	44
146	Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. <i>Rheumatology</i> , 2013, 52, 712-717.	0.9	18
147	Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists. <i>Pediatric Rheumatology</i> , 2013, 11, 48.	0.9	8
148	Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R217.	1.6	59
149	What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?. <i>Arthritis Research and Therapy</i> , 2013, 15, 213.	1.6	30
150	Canakinumab in pediatric rheumatic diseases. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 615-622.	1.4	8
151	Translational medicine from bedside to bench and back again: methotrexate revisited. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 291-306.	0.3	3
152	Brief Report: Anti-“Tumor Necrosis Factor” Targets Protein Kinase B/“Akt” Induced Resistance of Effector Cells to Suppression in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3279-3284.	6.7	29
153	Immunogenicity of the Bivalent Human Papillomavirus Vaccine in Adolescents with Juvenile Systemic Lupus Erythematosus or Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , 2013, 40, 1626-1627.	1.0	28
154	Effects of the Live Attenuated Measles-Mumps-Rubella Booster Vaccination on Disease Activity in Patients With Juvenile Idiopathic Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2449.	3.8	96
155	Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 745-752.	1.5	126
156	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 686-693.	0.5	109
157	Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?. <i>Rheumatology</i> , 2013, 52, 1674-1679.	0.9	35
158	Dr. de Rotte, et al reply. <i>Journal of Rheumatology</i> , 2013, 40, 536.2-536.	1.0	0
159	Using Registries to Identify Adverse Events in Rheumatic Diseases. <i>Pediatrics</i> , 2013, 132, e1384-e1394.	1.0	25
160	Changing winds in refractory autoimmune disease in children. <i>Current Opinion in Rheumatology</i> , 2012, 24, 267-273.	2.0	11
161	Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1991-1997.	0.5	103
162	Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 948-954.	0.5	70

#	ARTICLE	IF	CITATIONS
163	<i>ABCB1</i> and <i>ABCC3</i> Gene Polymorphisms Are Associated with First-year Response to Methotrexate in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 2032-2040.	1.0	64
164	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2396-2406.	13.9	588
165	Stem cells in pediatrics: state of the art and future perspectives. <i>Pediatric Research</i> , 2012, 71, 407-409.	1.1	7
166	Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). <i>Pediatric Rheumatology</i> , 2012, 10, 25.	0.9	18
167	Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). <i>Pediatric Rheumatology</i> , 2012, 10, 27.	0.9	20
168	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2385-2395.	13.9	716
169	Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1484-1489.	0.5	63
170	Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: A genotype-phenotype study. <i>Human Mutation</i> , 2012, 33, 561-571.	1.1	129
171	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. <i>Arthritis and Rheumatism</i> , 2012, 64, 557-567.	6.7	167
172	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. <i>Blood</i> , 2012, 120, 736-736.	0.6	0
173	Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis. <i>Current Stem Cell Research and Therapy</i> , 2011, 6, 3-9.	0.6	6
174	Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. <i>Blood</i> , 2011, 118, 1693-1698.	0.6	140
175	Awareness of Fabry disease among rheumatologists—current status and perspectives. <i>Clinical Rheumatology</i> , 2011, 30, 467-475.	1.0	15
176	High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score. <i>Arthritis and Rheumatism</i> , 2011, 63, 2007-2013.	6.7	126
177	Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 337-340.	0.5	29
178	Vaccination leads to an aberrant FOXP3 T-cell response in non-remitting juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2037-2043.	0.5	10
179	Defining Criteria for Macrophage Activation Syndrome, a Process Towards Early Recognition and Treatment. <i>Journal of Rheumatology</i> , 2011, 38, 593-594.	1.0	5
180	Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2340-7.	3.8	110

#	ARTICLE	IF	CITATIONS
181	Methotrexate does not exert immunomodulatory effects on regulatory T cells but on effector T cells. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A44-A44.	0.5	0
182	Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis – Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010. <i>Journal of Rheumatology</i> , 2011, 38, 2258-2263.	1.0	69
183	Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. <i>Journal of Rheumatology</i> , 2011, 38, 1441-1446.	1.0	66
184	IMMUNODEFICIENCIES AND THE RHEUMATIC DISEASES. , 2011, , 627-641.		0
185	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. <i>Blood</i> , 2011, 118, 3046-3046.	0.6	0
186	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <i>Arthritis Care and Research</i> , 2010, 62, 1533-1541.	1.5	84
187	Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission_{title}>A Randomized Clinical Trial</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1266.	3.8	229
188	The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1743-1752.	1.4	36
189	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010, 49, 441-449.	0.9	202
190	Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research?. <i>Rheumatology</i> , 2010, 49, 1200-1201.	0.9	9
191	Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. <i>Journal of Rheumatology</i> , 2010, 37, 665-667.	1.0	9
192	Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 602-610.e11.	1.5	385
193	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. <i>Blood</i> , 2010, 116, 2322-2322.	0.6	0
194	The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1 β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 883-891.	6.7	174
195	Defective phosphorylation of interleukin-18 receptor 1 β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2782-2793.	6.7	138
196	Fatal hemophagocytic lymphohistiocytosis in X-linked chronic granulomatous disease associated with a perforin gene variant. <i>Pediatric Blood and Cancer</i> , 2009, 52, 527-529.	0.8	26
197	Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. <i>Pediatric Rheumatology</i> , 2009, 7, 18.	0.9	57
198	S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. <i>Arthritis and Rheumatism</i> , 2008, 58, 3924-3931.	6.7	186

#	ARTICLE	IF	CITATIONS
199	Mesenchymal stem cells: A future for the treatment of arthritis?. <i>Joint Bone Spine</i> , 2008, 75, 379-382.	0.8	7
200	Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1385-1393.	2.0	44
201	Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. <i>Autoimmunity</i> , 2008, 41, 632-638.	1.2	32
202	Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2008, 111, 439-445.	0.6	216
203	Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. <i>Blood</i> , 2008, 111, 5233-5241.	0.6	84
204	Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1518-1524.	0.5	69
205	Recurrent and Opportunistic Infections in Children With Primary Intestinal Lymphangiectasia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 44, 382-385.	0.9	31
206	Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 589-598.	0.5	293
207	Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1384-1387.	0.5	98
208	Chapter 19 Autologous Stem Cell Transplantation (ASCT) for Drug Resistant Systemic Onset Juvenile Idiopathic Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, 6, 241-249.	0.1	0
209	Vaccination in autoimmune diseases: a blessing in disguise?. <i>Future Rheumatology</i> , 2007, 2, 153-162.	0.2	3
210	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. <i>Arthritis Research and Therapy</i> , 2007, 9, 301.	1.6	150
211	Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 639-646.	6.7	63
212	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2007, 57, 35-43.	6.7	121
213	A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3096-3106.	6.7	373
214	Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. <i>Blood</i> , 2006, 107, 1696-1702.	0.6	220
215	Refractory juvenile idiopathic arthritis: using autologous stem cell transplantation as a treatment strategy. <i>Expert Reviews in Molecular Medicine</i> , 2006, 8, 1-11.	1.6	12
216	Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: Introduction of the Dijkstra composite score. <i>Arthritis and Rheumatism</i> , 2005, 52, 2865-2872.	6.7	50

#	ARTICLE	IF	CITATIONS
217	Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. <i>Genetics in Medicine</i> , 2005, 7, 143-146.	1.1	87
218	IMMUNODEFICIENCIES AND THE RHEUMATIC DISEASES. , 2005, , 642-656.		1
219	Autologous stem cell transplantation for systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 168-176.	0.8	169
220	<i>Clostridium difficile</i> -associated reactive arthritis in two children. <i>Joint Bone Spine</i> , 2004, 71, 60-62.	0.8	35
221	Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. <i>Arthritis and Rheumatism</i> , 2004, 50, 1286-1295.	6.7	144
222	A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 2191-2201.	6.7	307
223	Anakinra in mutation-negative NOMID/CINCA syndrome: Comment on the articles by Hawkins et al and Hoffman and Patel. <i>Arthritis and Rheumatism</i> , 2004, 50, 3738-3739.	6.7	51
224	Refractory juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 277-289.	0.7	15
225	Myelodysplastic Features in Griscelli Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 275-276.	0.3	1
226	Radiologic features in juvenile idiopathic arthritis: A first step in the development of a standardized assessment method. <i>Arthritis and Rheumatism</i> , 2003, 48, 507-515.	6.7	78
227	Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2622-2626.	6.7	113
228	Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. <i>Blood</i> , 2003, 103, 1152-1157.	0.6	116
229	Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. <i>Blood</i> , 2002, 100, 4344-4350.	0.6	249
230	Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2002, 117, 965-972.	1.2	128
231	Identification of six novel WASP gene mutations in patients suffering from Wiskott-Aldrich syndrome. , 2000, 15, 386-387.		9
232	Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 628.	6.7	356
233	Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. <i>Nature Genetics</i> , 2000, 25, 173-176.	9.4	831
234	Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. <i>Current Rheumatology Reports</i> , 2000, 2, 316-323.	2.1	49

#	ARTICLE	IF	CITATIONS
235	Two Genes Are Responsible for Griscelli Syndrome at the Same 15q21 Locus. <i>Genomics</i> , 2000, 63, 299-306.	1.3	106
236	Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. <i>Lancet</i> , The, 1999, 353, 550-553.	6.3	188
237	Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study. <i>Arthritis and Rheumatism</i> , 1998, 41, 808-816.	6.7	186
238	RECOVERY FROM ADENOVIRUS PNEUMONIA IN A SEVERE COMBINED IMMUNODEFICIENCY PATIENT TREATED WITH INTRAVENOUS RIBAVIRIN. <i>Transplantation</i> , 1995, 59, 927.	0.5	27
239	Familial Cushing's Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease. <i>New England Journal of Medicine</i> , 1989, 321, 1659-1664.	13.9	118
240	Transition of Care in Rheumatology: Managing the Rheumatic Patient from Childhood to Adulthood. , O, , .		0